amycretin vs regor GLP-1

NCT06064006 · Phase 2 · completed

The study was randomized, quadruple-masked, and placebo-controlled, with 125 participants, providing a meaningful controlled design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

This trial's registered primary endpoint was safety (treatment-emergent adverse events); the figures shown are its prespecified secondary weight-change endpoints as published in The Lancet.

NCT06867718 · Phase 2 · completed

The trial randomized 267 participants to four active-dose groups or placebo and masked both participants and investigators. Its primary endpoint was percent change in body weight at Week 36, but the registry does not report whether the comparison met its statistical objective, so the evidence is currently limited to a well-controlled study design with an unknown result.

NCT06542874 · Phase 2 · completed

This was a randomized, quadruple-blinded, placebo-controlled trial with 448 participants and a validated diabetes disease-control endpoint (HbA1c). The primary comparison was clearly positive, with HbA1c reductions of up to 1.8 percentage points (subcutaneous) and 1.5 points (oral) that were statistically significant against placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.